Spanish pharmaceutical company Almirall, and Meda, based in Sweden, have entered into an agreement regarding Meda's inhalation products division — the business sector that develops the Novolizer, a multidose dry-powder inhaler for administration of products to treat respiratory conditions.
Through the agreement, Meda will market the Novolizer products currently on the market, while Almirall will take over continued R&D for pharmaceutical substances, including Almirall´s pipeline products, with the Novolizer system.
For several years, an agreement has existed with Almirall for the development
of one of its leading respiratory pipeline products, LAS34273 — a long-acting
anticholinergic compound for the treatment of chronic obstructive pulmonary
disorder — in the Novolizer. The partnership has been strengthened through
Almirall's acquisition of Meda's development unit and intellectual property
rights to the Novolizer technology, the companies said.
